Gsk (GSK) Tax Provisions (2009 - 2026)

Gsk's Tax Provisions history runs 18 years deep, the most recent figure standing at $267.0 million for Q2 2026.

• In Q2 2026, Tax Provisions rose 183.05% year-over-year to $267.0 million; the TTM figure through Jun 2026 stood at -$2.0 billion (down 44.12% YoY), while the FY2025 annual figure was $1.5 billion, up 118.06% from the prior year.
• Tax Provisions for Q2 2026 stood at $267.0 million, up from -$411.2 million in the prior quarter.
• The five-year high for Tax Provisions was $347.6 million in Q1 2024, with the low at -$1.5 billion in Q4 2025.
• The 5-year median for Tax Provisions is -$323.5 million (2023), against an average of -$350.8 million.
• The sharpest annual moves came in 2025 and 2026: Tax Provisions plunged 32502.13% in 2025, then surged 183.05% in 2026.
• Gsk's Tax Provisions stood at -$829.3 million in 2022, then decreased by 13.15% to -$938.3 million in 2023, then rose by 28.05% to -$675.1 million in 2024, then sank by 119.09% to -$1.5 billion in 2025, then surged by 118.05% to $267.0 million in 2026.
• Business Quant data shows GSK's Tax Provisions at $267.0 million in Q2 2026, -$411.2 million in Q1 2026, and -$1.5 billion in Q4 2025.